News

Double-unit cord blood transplants don't boost survival


 

AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY

"What this showed us is that it’s not just receiving a double perhaps that has some benefit for some patients, but also the conditioning regimen that we had changed simultaneously at the University of Minnesota," Dr. Wagner said.

He also highlighted similar findings from a very recent study he coauthored that reported comparable adjusted risks of neutrophil recovery, transplant-related mortality, and overall mortality after double UCB and adequately dosed single UCB transplants in 409 adults with acute leukemia (Blood 2012 Dec. 9 [Epub ahead of print]).

The study was supported by the National Heart, Lung, and Blood Institute; the National Cancer Institute; and the Children’s Oncology Group. Dr. Wagner and his coauthors reported no relevant conflicts of interest.

p.wendling@elsevier.com

Pages

Recommended Reading

HEM-ONC CHAT: Dr. Elias Jabbour, 'Treatment a la Carte in CML'
MDedge Family Medicine
ASH12: New Myeloma Drug Works Better with Low-Dose Dexamethasone
MDedge Family Medicine
FDA approves abiraterone use ahead of prostate cancer chemotherapy
MDedge Family Medicine
HERA: Trastuzumab survival benefit strong at 8 years
MDedge Family Medicine
Ten-year data back shorter radiotherapy for breast cancer
MDedge Family Medicine
'Chemobrain' starts before chemotherapy in breast cancer study
MDedge Family Medicine
Diabetes confers 27% increase in breast cancer risk
MDedge Family Medicine
Genes predict adjuvant trastuzumab outcomes in HER2-positive breast cancer
MDedge Family Medicine
More women receiving Pap tests as recommended
MDedge Family Medicine
FDA proposal encourages development of abuse deterrent opioids
MDedge Family Medicine